Li T, Gibiansky L, Parikh A, van der Linden M, Sanghavi K, Putnins M
Clin Pharmacokinet. 2024; 64(1):127-141.
PMID: 39708278
DOI: 10.1007/s40262-024-01464-2.
Jackson D, Ulldemolins M, Liu X, Harris C, Tognolini A, Wallis S
Antimicrob Agents Chemother. 2024; 68(12):e0111624.
PMID: 39480073
PMC: 11619375.
DOI: 10.1128/aac.01116-24.
Alli A, Paruk F, Roger C, Lipman J, Calleemalay D, Wallis S
PLoS One. 2023; 18(9):e0291425.
PMID: 37729151
PMC: 10511078.
DOI: 10.1371/journal.pone.0291425.
Baklouti S, Comets E, Gandia P, Concordet D
Clin Pharmacokinet. 2023; 62(11):1599-1609.
PMID: 37717242
PMC: 10581936.
DOI: 10.1007/s40262-023-01296-6.
El Hassani M, Marsot A
Clin Pharmacokinet. 2023; 62(4):533-540.
PMID: 37004650
DOI: 10.1007/s40262-023-01233-7.
Breakthrough: a first-in-class virtual simulator for dose optimization of ACE inhibitors in translational cardiovascular medicine.
Schneider B, Ward J, Sotillo S, Garelli-Paar C, Guillot E, Prikazsky M
Sci Rep. 2023; 13(1):3300.
PMID: 36843132
PMC: 9968717.
DOI: 10.1038/s41598-023-30453-x.
Population Pharmacokinetics of Ganciclovir in Allogeneic Hematopoietic Stem Cell Transplant Patients.
Selby P, Heffernan A, Yeung D, Warner M, Peake S, Hahn U
Antimicrob Agents Chemother. 2023; 67(3):e0155022.
PMID: 36815858
PMC: 10019199.
DOI: 10.1128/aac.01550-22.
Development of a Model-Informed Dosing Tool to Optimise Initial Antibiotic Dosing-A Translational Example for Intensive Care Units.
Weinelt F, Stegemann M, Theloe A, Pfafflin F, Achterberg S, Schmitt L
Pharmaceutics. 2021; 13(12).
PMID: 34959409
PMC: 8708464.
DOI: 10.3390/pharmaceutics13122128.
Optimizing gentamicin dosing in different pediatric age groups using population pharmacokinetics and Monte Carlo simulation.
Ghoneim R, Thabit A, Lashkar M, Ali A
Ital J Pediatr. 2021; 47(1):167.
PMID: 34362436
PMC: 8343923.
DOI: 10.1186/s13052-021-01114-4.
Population pharmacokinetic and exposure-response analyses of intravenous and subcutaneous rituximab in patients with chronic lymphocytic leukemia.
Gibiansky E, Gibiansky L, Chavanne C, Frey N, Jamois C
CPT Pharmacometrics Syst Pharmacol. 2021; 10(8):914-927.
PMID: 34110098
PMC: 8376135.
DOI: 10.1002/psp4.12665.
Antibiotics in Adult Cystic Fibrosis Patients: A Review of Population Pharmacokinetic Analyses.
El Hassani M, Caissy J, Marsot A
Clin Pharmacokinet. 2021; 60(4):447-470.
PMID: 33447944
DOI: 10.1007/s40262-020-00970-3.
Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma.
Lu D, Lu T, Shi R, Gibiansky L, Agarwal P, Shemesh C
Pharm Res. 2020; 37(12):252.
PMID: 33258982
PMC: 7708381.
DOI: 10.1007/s11095-020-02933-6.
Mechanistic Population Pharmacokinetic Model of Oseltamivir and Oseltamivir Carboxylate Accounting for Physiological Changes to Predict Exposures in Neonates and Infants.
Gibiansky L, Ravva P, Parrott N, Bhardwaj R, Zwanziger E, Grimsey P
Clin Pharmacol Ther. 2020; 108(1):126-135.
PMID: 31957010
PMC: 7325316.
DOI: 10.1002/cpt.1791.
Integrated Two-Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non-Hodgkin Lymphoma.
Lu D, Lu T, Gibiansky L, Li X, Li C, Agarwal P
CPT Pharmacometrics Syst Pharmacol. 2019; 9(1):48-59.
PMID: 31749251
PMC: 6966185.
DOI: 10.1002/psp4.12482.
Vancomycin Population Pharmacokinetics in Critically Ill Adults During Sustained Low-Efficiency Dialysis.
Kanji S, Roberts J, Xie J, Zelenitsky S, Hiremath S, Zhang G
Clin Pharmacokinet. 2019; 59(3):327-334.
PMID: 31471789
DOI: 10.1007/s40262-019-00817-6.
Vancomycin population pharmacokinetics for adult patients with sepsis or septic shock: are current dosing regimens sufficient?.
Heffernan A, Germano A, Sime F, Roberts J, Kimura E
Eur J Clin Pharmacol. 2019; 75(9):1219-1226.
PMID: 31154476
DOI: 10.1007/s00228-019-02694-1.
Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study.
Gibiansky E, Gibiansky L, Buchheit V, Frey N, Brewster M, Fingerle-Rowson G
Br J Clin Pharmacol. 2019; 85(9):1935-1945.
PMID: 31050355
PMC: 6710522.
DOI: 10.1111/bcp.13974.
Fuzzy Evaluation of Pharmacokinetic Models.
Sepulveda C, Montiel O, Cornejo Bravo J, Sepulveda R
Comput Intell Neurosci. 2019; 2018:1983897.
PMID: 30728832
PMC: 6341258.
DOI: 10.1155/2018/1983897.
Population Pharmacokinetic Analyses and Model Validation of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease.
Lanke S, Shoaf S
J Clin Pharmacol. 2019; 59(5):763-770.
PMID: 30618157
PMC: 6590359.
DOI: 10.1002/jcph.1370.
Population Pharmacokinetic Modelling for Estimation of Remifentanil Metabolic-Ratio Using Non-steady-State Concentrations under Rapidly Adaptive Dosing.
Simeoni M, Chen C
Pharm Res. 2018; 35(11):216.
PMID: 30255401
DOI: 10.1007/s11095-018-2508-0.